{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:44:57Z","timestamp":1790934297795,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>We compared failure patterns in patients with inoperable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) alone versus CRT combined with sequential and\/or concurrent immune checkpoint inhibitors (CRT-IO).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective real-world data from 221 patients across two German tertiary cancer centers were analyzed. Of these, 74 received CRT-IO, including sequential durvalumab (85%) and concurrent\/sequential nivolumab (15%), while 148 received CRT alone. First failure site and time to failure were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between 2012 and 2022, all patients received thoracic radiotherapy (\u2265\u200960\u00a0Gy) and at least two cycles of platinum-based chemotherapy. Induction chemotherapy was administered in 36%, and induction chemo-immunotherapy in 2%. Median follow-up was 51.7\u00a0months (95% CI 47.0\u201356.4). Median overall survival (OS) for the entire cohort was 37.1\u00a0months (95% CI 26.0\u201348.2), with OS in the CRT-IO group not reached vs. 27.1\u00a0months (95% CI 18.5\u201325.7) in the CRT group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Median progression-free survival (PFS) was 22.8\u00a0months (95% CI 6.4\u201339.1) for CRT-IO versus. 9.9\u00a0months (95% CI 7.0\u201312.8) for CRT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001, see Fig.\u00a01).\n                    <\/jats:p>\n                    <jats:p>\n                      Failure patterns differed significantly. CRT-IO patients had lower loco-regional progression (LRP) rates (9.5% vs. 21.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.023) and were more frequently alive without progression (45.9% vs. 16.3%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Brain metastasis (BM) as the first failure, multifocal progression (MFP) and isolated extracranial distant metastasis (ecDM) rates were comparable between the CRT and CRT-IO subgroup. Women had a higher risk of isolated BM (17.3% vs. 6.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016), whereas squamous cell carcinoma (SCC) patients had higher LRP rates (25.3% vs. 13.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016). Median post-progression survival (PPS) was 19.4\u00a0months (95% CI 16.8\u201322.0) for CRT-IO and 9.5\u00a0months (95% CI 5.8\u201313.1) for CRT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.207). PPS was longer after BM (19.9\u00a0months) vs. LRP (8.5\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.076) and significantly better in women (20.7 vs. 8.9\u00a0months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) and adenocarcinoma\/non-otherwise-specified-carcinoma (AC\/NOS) vs. SCC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CRT-IO significantly improves OS, PFS, and LRP control compared to CRT alone. Failure patterns and survival disparities by histology and gender suggest tailored surveillance and treatment strategies are needed. Further studies should optimize management of LRP and long-term outcomes in CRT-IO-treated patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-025-06355-y","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:31:57Z","timestamp":1762003917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immune checkpoint inhibition alters patterns of failure in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy"],"prefix":"10.1007","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-1202","authenticated-orcid":false,"given":"Julian","family":"Taugner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silja","family":"Stamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hofstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Clasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hartig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorben","family":"Gro\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"issue":"19","key":"6355_CR1","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-22-3949","volume":"29","author":"DP Anobile","year":"2023","unstructured":"Anobile DP, Salaroglio IC, Tabbo F, La Vecchia S, Akman M, Napoli F, Bungaro M, Benso F, Aldieri E, Bironzo P, Kopecka J, Passiglia F, Righi L, Novello S, Scagliotti GV, Riganti C (2023) Autocrine 17-beta-Estradiol\/Estrogen receptor-alpha loop determines the response to immune checkpoint inhibitors in non-small cell lung cancer. Clin Cancer Res 29(19):3958\u20133973. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3949","journal-title":"Clin Cancer Res"},{"issue":"20","key":"6355_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"issue":"24","key":"6355_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, \u00d6zg\u00fcro\u011flu M (2018) Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342\u20132350. https:\/\/doi.org\/10.1056\/NEJMoa1809697","journal-title":"N Engl J Med"},{"issue":"13","key":"6355_CR4","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Auperin","year":"2010","unstructured":"Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181\u20132190. https:\/\/doi.org\/10.1200\/JCO.2009.26.2543","journal-title":"J Clin Oncol"},{"issue":"3","key":"6355_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.athoracsur.2004.02.067","volume":"78","author":"RJ Cerfolio","year":"2004","unstructured":"Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA (2004) The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78(3):1017\u20131023. https:\/\/doi.org\/10.1016\/j.athoracsur.2004.02.067","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"6355_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s00066-016-0941-8","volume":"192","author":"M Flentje","year":"2016","unstructured":"Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, Dickgreber N, Vaissiere N, De Almeida C, Edlich B, Fietkau R (2016) GILT\u2013a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol 192(4):216\u2013222. https:\/\/doi.org\/10.1007\/s00066-016-0941-8","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"6355_CR7","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s00432-022-04174-z","volume":"149","author":"B Florsch","year":"2023","unstructured":"Florsch B, Taugner J, Kasmann L, Kenndoff S, Guggenberger J, Tufman A, Reinmuth N, Duell T, Belka C, Eze C, Manapov F (2023) Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +\/- immune checkpoint inhibition: a decade-long single-center historical analysis. J Cancer Res Clin Oncol 149(7):3267\u20133276. https:\/\/doi.org\/10.1007\/s00432-022-04174-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"6355_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.005","author":"C Friedes","year":"2024","unstructured":"Friedes C, Iocolano M, Lee SH, Li B, Duan L, Levin WP, Cengel KA, Sun LL, Aggarwal C, Marmarelis ME, Doucette A, Cohen RB, Xiao Y, Langer CJ, Bradley J, Feigenberg SJ, Yegya-Raman N (2024) Patterns of failure, low-volume relapse, and subsequent ablative management in locally advanced non-small cell lung cancer treated with definitive chemoradiation and consolidation immune checkpoint inhibitors. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.10.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6355_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2013.12.002","author":"S Garg","year":"2014","unstructured":"Garg S, Gielda BT, Kiel K, Turian JV, Fidler MJ, Batus M, Bonomi P, Sher DJ (2014) Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2013.12.002","journal-title":"Pract Radiat Oncol"},{"key":"6355_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-023-02175-6","author":"K Hofstetter","year":"2024","unstructured":"Hofstetter K, Taugner J, Kasmann L, Mansoorian S, Florsch B, Eze C, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F (2024) First-site-metastasis pattern in patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a retrospective analysis. Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-023-02175-6","journal-title":"Strahlenther Onkol"},{"key":"6355_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.07.001","author":"Y Kakiuchi","year":"2024","unstructured":"Kakiuchi Y, Saruwatari K, Murotani K, Tokito T, Iriki T, Iwakawa J, Sakata Y, Shingu N, Saeki S, Inaba M, Takaki A, Misono S, Suetsugu T, Azuma K, Mizuno K, Sakagami T (2024) Real-world efficacy and safety of durvalumab administration following chemoradiotherapy in elderly patients with unresectable locally advanced nonsmall cell lung cancer: a multicenter retrospective Study. Clin Lung Cancer. https:\/\/doi.org\/10.1016\/j.cllc.2024.07.001","journal-title":"Clin Lung Cancer"},{"key":"6355_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-021-01091-y","author":"Y Katagiri","year":"2021","unstructured":"Katagiri Y, Jingu K, Yamamoto T, Matsushita H, Umezawa R, Ishikawa Y, Takahashi N, Takeda K, Tasaka S, Kadoya N (2021) Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. Jpn J Radiol. https:\/\/doi.org\/10.1007\/s11604-021-01091-y","journal-title":"Jpn J Radiol"},{"key":"6355_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030887","author":"N Kita","year":"2023","unstructured":"Kita N, Tomita N, Takaoka T, Sudo S, Tsuzuki Y, Okazaki D, Niwa M, Torii A, Takano S, Niimi A, Hiwatashi A (2023) Comparison of recurrence patterns between adenocarcinoma and squamous cell carcinoma after stereotactic body radiotherapy for early-stage lung cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15030887","journal-title":"Cancers (Basel)"},{"issue":"25","key":"6355_CR14","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMoa022136","volume":"348","author":"D Lardinois","year":"2003","unstructured":"Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348(25):2500\u20132507. https:\/\/doi.org\/10.1056\/NEJMoa022136","journal-title":"N Engl J Med"},{"key":"6355_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X, Ahn MJ, Quang LV, Soparattanapaisarn N, Inoue T, Wang CL, Huang M, Yang JC, Cobo M, Ozguroglu M, Casarini I, Khiem DV, Sriuranpong V, Cronemberger E, Takahashi T, Runglodvatana Y, Chen M, Investigators LT (2024) Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2402614","journal-title":"N Engl J Med"},{"key":"6355_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.02.021","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Kageyama SI, Niho S, Okumura M, Hojo H, Motegi A, Nakamura N, Zenda S, Yoh K, Goto K, Akimoto T (2019) Impact of EGFR mutation and ALK translocation on recurrence pattern after definitive chemoradiotherapy for inoperable stage III non-squamous non-small-cell lung cancer. Clin Lung Cancer. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.021","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"6355_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","volume":"127","author":"U Nestle","year":"2018","unstructured":"Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pottgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePechoux C, Van Houtte P (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127(1):1\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2018.02.023","journal-title":"Radiother Oncol"},{"key":"6355_CR35","doi-asserted-by":"publisher","unstructured":"Noriko K, Yukinori M, Takashi S, Masakazu O, Takamasa M, Norio A, Kota F, Setsuko O, Kiyoshi N, Takahiro K, Tomoko A, Takashi S, Shuji O, Tomohiro K, Masaru N, Satsuki F, Yusuke I, Hiroaki O, Toyohiro H, Takashi M, Kyoto R (2023) Oncology Study Group (KROSG), Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer, J  Radiation Res 64(1):142\u2013153 https:\/\/doi.org\/10.1093\/jrr\/rrac057","DOI":"10.1093\/jrr\/rrac057"},{"issue":"4","key":"6355_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jtho.2017.12.011","volume":"13","author":"L Nygard","year":"2018","unstructured":"Nygard L, Vogelius IR, Fischer BM, Kjaer A, Langer SW, Aznar MC, Persson GF, Bentzen SM (2018) A competing risk model of first failure site after definitive chemoradiation therapy for locally advanced non-small cell lung cancer. J Thorac Oncol 13(4):559\u2013567. https:\/\/doi.org\/10.1016\/j.jtho.2017.12.011","journal-title":"J Thorac Oncol"},{"key":"6355_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002140.pub3","author":"N O'Rourke","year":"2010","unstructured":"O\u2019Rourke N, Roque IFM, Farre Bernado N, Macbeth F (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002140.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"6355_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.030","author":"J Rutkowski","year":"2019","unstructured":"Rutkowski J, Saad ED, Burzykowski T, Buyse M, Jassem J (2019) Chronological trends in progression-free, overall, and post-progression survival in first-line therapy for advanced NSCLC. J Thorac Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.030","journal-title":"J Thorac Oncol"},{"key":"6355_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.3.198","author":"WT Sause","year":"1995","unstructured":"Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, Emami B, Curran WJ, Byhardt RW, Turrisi AT et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/87.3.198","journal-title":"J Natl Cancer Inst"},{"key":"6355_CR22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02748","author":"BJ Schneider","year":"2020","unstructured":"Schneider BJ, Ismaila N, Aerts J, Chiles C, Daly ME, Detterbeck FC, Hearn JWD, Katz SI, Leighl NB, Levy B, Meyers B, Murgu S, Nekhlyudov L, Santos ES, Singh N, Tashbar J, Yankelevitz D, Altorki N (2020) Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.02748","journal-title":"J Clin Oncol"},{"key":"6355_CR23","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.09.19","author":"J Taugner","year":"2019","unstructured":"Taugner J, Kasmann L, Eze C, Dantes M, Roengvoraphoj O, Gennen K, Karin M, Petruknov O, Tufman A, Belka C, Manapov F (2019) Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. Transl Lung Cancer Res. https:\/\/doi.org\/10.21037\/tlcr.2019.09.19","journal-title":"Transl Lung Cancer Res"},{"key":"6355_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01590-8","author":"J Taugner","year":"2020","unstructured":"Taugner J, Eze C, Kasmann L, Roengvoraphoj O, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C, Manapov F (2020) Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer. Radiat Oncol. https:\/\/doi.org\/10.1186\/s13014-020-01590-8","journal-title":"Radiat Oncol"},{"key":"6355_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01091-9","author":"J Taugner","year":"2021","unstructured":"Taugner J, Kasmann L, Eze C, Ruhle A, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F (2021) Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs. https:\/\/doi.org\/10.1007\/s10637-021-01091-9","journal-title":"Invest New Drugs"},{"key":"6355_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05584-w","author":"M Unterrainer","year":"2022","unstructured":"Unterrainer M, Taugner J, Kasmann L, Tufman A, Reinmuth N, Li M, Mittlmeier LM, Bartenstein P, Kunz WG, Ricke J, Belka C, Eze C, Manapov F (2022) Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy +\/- immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-021-05584-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6355_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3569","author":"Vokes, E. E., Herndon, J. E., 2nd, Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., Green, M. R., Cancer, & Leukemia Group, B","year":"2007","unstructured":"Vokes, E. E., Herndon, J. E., 2nd, Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., Green, M. R., Cancer, & Leukemia Group, B (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2006.07.3569","journal-title":"J Clin Oncol"},{"issue":"5","key":"6355_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/01243894-200606000-00011","volume":"1","author":"HA Wakelee","year":"2006","unstructured":"Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH, Eastern CooperativeOncology G, G. (2006) Survival differences by sex for patients with advanced non-small cell lung cancer on eastern cooperative oncology group trial 1594. J Thorac Oncol 1(5):441\u2013446","journal-title":"J Thorac Oncol"},{"key":"6355_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00451-X","author":"V Westeel","year":"2022","unstructured":"Westeel V, Foucher P, Scherpereel A, Domas J, Girard P, Tredaniel J, Wislez M, Dumont P, Quoix E, Raffy O, Braun D, Derollez M, Goupil F, Hermann J, Devin E, Barbieux H, Pichon E, Debieuvre D, Ozenne G, Muir J-F, Dehette S, Virally J, Grivaux M, Lebargy F, Souquet P-J, Freijat FA, Girard N, Courau E, Azarian R, Farny M, Duhamel J-P, Langlais A, Morin F, Milleron B, Zalcman G, Barlesi F (2022) Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(22)00451-X","journal-title":"Lancet Oncol"},{"key":"6355_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq067","author":"P Wheatley-Price","year":"2010","unstructured":"Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, Qian W, Hackshaw A, Rudd R, Booton R, Danson S, Lorigan P, Thatcher N, Shepherd FA (2010) The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdq067","journal-title":"Ann Oncol"},{"key":"6355_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.642883","author":"Y Xu","year":"2021","unstructured":"Xu Y, Li H, Fan Y (2021) Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.642883","journal-title":"Front Oncol"},{"key":"6355_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1281888","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang J, Zhang T, Zhou Z, Wang Y, Jiang Y, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Wang W, Xue Q, Wang J, Li YX, Bi N (2023) Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1281888","journal-title":"Front Immunol"},{"key":"6355_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz259.008","author":"X Zhu","year":"2019","unstructured":"Zhu X, Fu X (2019) Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: establishment and internal validation of a nomogram based on the clinicopathological factors. Ann Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdz259.008","journal-title":"Ann Oncol"},{"key":"6355_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-1467-x","author":"X Zhu","year":"2020","unstructured":"Zhu X, Hou R, Li X, Jiang C, Xia W, Fu X (2020) Predictive model of the first failure pattern in patients receiving definitive chemoradiotherapy for inoperable locally advanced non-small cell lung cancer (LA-NSCLC). Radiat Oncol. https:\/\/doi.org\/10.1186\/s13014-020-1467-x","journal-title":"Radiat Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06355-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T19:39:03Z","timestamp":1765654743000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06355-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6355"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06355-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7104081\/v1","asserted-by":"object"}]},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"All patients gave written informed consent. This retrospective analysis is in compliance with the principles of the Declaration of Helsinki and its subsequent amendments. This work was approved by the Ethics Committee of the Ludwig Maximilian University of Munich and by the Ethics Committee of the Eberhard Karls University of Tuebingen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"313"}}